aav8-hfix19
Gene therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01620801)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor IXSupplementation
F9 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav8-hfix19
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01620801 | Phase 1 | Oct 1, 2012 | Spark Therapeutics, Trinity College Dublin, University of Pennsylvania, University of Pittsburgh, University of Sydney |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spark Therapeutics | For profit | 1 | 1 | 1 | 2012 |
| Trinity College Dublin | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1